Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 4 |
List of Tables | 5 | 1 |
List of Figures | 5 | 1 |
Introduction | 6 | 1 |
Global Markets Direct Report Coverage | 6 | 1 |
Sinusitis Overview | 7 | 1 |
Therapeutics Development | 8 | 1 |
Pipeline Products for Sinusitis Overview | 8 | 1 |
Sinusitis Therapeutics under Development by Companies | 9 | 2 |
Sinusitis Pipeline Products Glance | 11 | 3 |
Late Stage Products | 11 | 1 |
Clinical Stage Products | 12 | 1 |
Early Stage Products | 13 | 1 |
Sinusitis Products under Development by Companies | 14 | 1 |
Sinusitis Companies Involved in Therapeutics Development | 15 | 12 |
AmpliPhi Biosciences Corporation | 15 | 1 |
F. Hoffmann-La Roche Ltd. | 16 | 1 |
Knopp Biosciences LLC | 17 | 1 |
Kyorin Pharmaceutical Co., Ltd. | 18 | 1 |
Kyowa Hakko Kirin Co., Ltd. | 19 | 1 |
Merck &Co., Inc. | 20 | 1 |
Oticpharma Ltd | 21 | 1 |
Paratek Pharmaceuticals, Inc. | 22 | 1 |
Pfizer Inc. | 23 | 1 |
Quorum Innovations LLC | 24 | 1 |
Regeneron Pharmaceuticals Inc | 25 | 1 |
Therabron Therapeutics, Inc. | 26 | 1 |
Sinusitis Therapeutics Assessment | 27 | 9 |
Assessment by Monotherapy Products | 27 | 1 |
Assessment by Target | 28 | 2 |
Assessment by Mechanism of Action | 30 | 2 |
Assessment by Route of Administration | 32 | 2 |
Assessment by Molecule Type | 34 | 2 |
Drug Profiles | 36 | 50 |
ABSA-01 Drug Profile | 36 | 2 |
benralizumab Drug Profile | 38 | 4 |
CG-201 Drug Profile | 42 | 1 |
dexpramipexole dihydrochloride Drug Profile | 43 | 3 |
dupilumab Drug Profile | 46 | 6 |
fluticasone propionate Drug Profile | 52 | 2 |
KRPAM-1977X Drug Profile | 54 | 2 |
omadacycline tosylate Drug Profile | 56 | 6 |
omalizumab Drug Profile | 62 | 4 |
P-008 Drug Profile | 66 | 1 |
PCL-1404 Drug Profile | 67 | 1 |
PF-06817024 Drug Profile | 68 | 1 |
Qi-117 Drug Profile | 69 | 1 |
RG-6149 Drug Profile | 70 | 1 |
Small Molecule for Sinusitis Drug Profile | 71 | 1 |
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Sinusitis and Allergic Rhinitis Drug Profile | 72 | 1 |
Small Molecules for Chronic Rhinosinusitis Drug Profile | 73 | 1 |
solithromycin Drug Profile | 74 | 12 |
Sinusitis Dormant Projects | 86 | 1 |
Sinusitis Product Development Milestones | 87 | 5 |
Featured News &Press Releases | 87 | 1 |
Aug 09, 2016: AmpliPhi Biosciences Confirms Clinical Trial Progress | 87 | 1 |
Aug 03, 2016: AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus | 87 | 1 |
Apr 20, 2016: AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort | 88 | 1 |
Feb 03, 2016: Nasal polyps can be treated with medicine dupilumab | 88 | 1 |
Feb 02, 2016: Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association | 89 | 1 |
Jan 20, 2016: AmpliPhi Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial of AB-SA01 | 89 | 1 |
Nov 19, 2015: AmpliPhi Signs Clinical Trial Agreement with University of Adelaide to Conduct a Phase I Trial of Bacteriophage Therapy for Treating Staphylococcus aureus Infections | 90 | 1 |
Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets | 90 | 1 |
Sep 30, 2014: Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps | 91 | 1 |
Appendix | 92 | 2 |
Methodology | 92 | 1 |
Coverage | 92 | 1 |
Secondary Research | 92 | 1 |
Primary Research | 92 | 1 |
Expert Panel Validation | 92 | 1 |
Contact Us | 92 | 1 |
Disclaimer | 93 | 1 |